Vasopharm Biotech

vasopharm is a privately held pharmaceutical company based in Würzburg, Germany, dedicated to developing novel therapeutics for the treatment of cerebrovascular diseases and traumatic brain injury (TBI). The company's lead clinical candidate is Ronopterin (VAS203), a selective inhibitor of inducible nitric oxide synthase (iNOS) designed to reduce intracranial pressure and improve neurological outcomes following moderate to severe TBI. Despite a challenging Phase 3 trial (NOSTRA III) that failed to meet its primary endpoint in the overall population, the company continues to evaluate the drug's potential in specific patient subgroups. vasopharm's approach focuses on modulating the inflammatory response and metabolic changes that occur in the brain after injury. The company remains a key player in the niche field of neuroprotection for acute brain trauma.